Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) announced its earnings results on Thursday. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01), Zacks reports.
Eupraxia Pharmaceuticals Price Performance
NASDAQ:EPRX traded down $0.18 during trading hours on Monday, hitting $3.65. The company's stock had a trading volume of 6,276 shares, compared to its average volume of 16,524. The company has a market capitalization of $129.93 million and a P/E ratio of -5.06. Eupraxia Pharmaceuticals has a twelve month low of $2.20 and a twelve month high of $4.48. The stock has a fifty day simple moving average of $3.49 and a 200-day simple moving average of $3.11.
Wall Street Analysts Forecast Growth
Separately, Craig Hallum assumed coverage on Eupraxia Pharmaceuticals in a report on Friday, February 21st. They issued a "buy" rating and a $12.00 price objective for the company.
Get Our Latest Stock Analysis on EPRX
Eupraxia Pharmaceuticals Company Profile
(
Get Free Report)
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.
See Also
Before you consider Eupraxia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eupraxia Pharmaceuticals wasn't on the list.
While Eupraxia Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
